Total
0
Shares
Holista CollTech (ASX:HCT) - CEO, Rajen Manickavasagar
CEO, Rajen Manickavasagar
Source: The Edge TV
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Holista CollTech’s (HCT) Path-Away ingredient has proven to be more than 99.99 per cent effective against the feline coronavirus
  • Path-Away is a plant-based ingredient that is found in Holista’s NatShield hand sanitiser
  • It works by crippling a virus’ cell walls, causing bacteria to group together and destroy themselves within seconds
  • Holista has confirmed that 99.99 per cent of the coronavirus was killed within a minute of being exposed to NatShield
  • Path-Away will now be subject to further testing to assess its efficacy against COVID-19 via a more direct method such as inoculation
  • Results from this are expected to be released as soon as testing is completed
  • Based off this news, Holista is up a steady 14.7 per cent and shares are trading for 19.5 cents each

Holista CollTech’s (HCT) Path-Away ingredient has proven to be more than 99.99 per cent effective against the feline coronavirus.

The feline coronavirus is a substitute of the COVID-19 coronavirus found in humans.

What is Path-Away?

Path-Away is an active plant-based ingredient used in Holista’s NatShield alcohol-free hand sanitiser and it works by crippling a virus’ cell walls, causing bacteria to group together and destroy themselves within seconds.

Testing began in mid-March at microbiology laboratory in the United Kingdom to determine the efficacy of the ingredient against COVID-19.

Ingredients in Path-Away are Generally Regarded As Safe (GRAS) certified, approved by the Food and Drug Administration (FDA), and are exempt by the Environmental Protection Agency (EPA) under FIRFA 25(b) (Federal Insecticide, Fungicide and Rodenticide Act) as it is of minimal risk to humans and pets.

Path-Away has also been approved by the American Food and Safety Authority, and the Environmental Protection Authority of New Zealand.

It is developed in South Carolina by Global Infections Control Consultants LLC (GICC LLC).

As Path-Away has already proven effective against a range of viruses, fungi and bacteria, Holista and GICC LLC decided to test it against a substitute of COVID-19.

Results

Holista has confirmed that 99.99 per cent of the coronavirus was killed within a minute of being exposed to NatShield at a concentration of three per cent.

“Path-Away was subjected to high international standards of testing against COVID-19 and we are elated by the results,” GICC LLC President Dr Arthur V. Martin commented.

“We hope these results will advance the global efforts to combat the spread of this coronavirus, future contagions and even the common flu by something very natural and environmentally friendly,” he added.

Holista is currently in the process of registering NatShield in Australia with the Therapeutic Goods Administration (TGA) and will apply for a permit claiming that it is effective against COVID-19 as per the TGA’s guidelines.

However, if this permit is not granted then it will not grant NatShield as effective against COVID-19.

“This is highly significant for NatShield. The results have satisfied the European standard that applies to areas and situations where disinfection is medically indicated,” Holista CEO Dr Rajen Manicka stated.

“This scientific validation means that NatShield can be used to sanitise the hands without the need for rinsing, can be applied to the face and even inside the nose without irritation and is not harmful even if swallowed,” he continued.

“It may also be sprayed safely to sanitise a person’s immediate surrounding space, without any negative effects,” he said.

What’s next?

Path-Away will now be subject to further testing to assess its efficacy against COVID-19 via a more direct method such as inoculation (inducting immunity against diseases or viruses, similar to a vaccination or immunisation).

This testing is being completed at Biosafety Laboratory approved by the Centres for Disease Control in the United Stares.

Results from this are expected to be released as soon as testing is completed.

Based off this news, Holista is up a steady 14.7 per cent and shares are trading for 19.5 cents each at 12:10 pm AEST.

HCT by the numbers
More From The Market Herald
(ASX:ATH) -

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.